Computational prediction and analysis of the DR6-NAPP interaction
Sergei Y Ponomarev1, Joseph Audie
1CMD Bioscience, LLC, 554 Boston Post Rd #318, Orange, Connecticut 06477, USA.
Proteins
|February 22, 2011
Summary
This study computationally models the interaction between death receptor 6 (DR6) and the amyloid precursor protein fragment (NAPP). The findings offer structural insights into Alzheimer's disease (AD) mechanisms and potential drug design.
Area of Science:
- Neuroscience
- Biochemistry
- Computational Biology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no effective treatments.
- A proposed biochemical model involves a protein-protein interaction between death receptor 6 (DR6) and an N-terminal fragment of amyloid precursor protein (NAPP).
Purpose of the Study:
- To computationally model the structural and energetic aspects of the DR6 ectodomain and NAPP interaction.
- To provide a mechanistic interpretation of DR6-NAPP binding and its potential role in spontaneous apoptosis.
Main Methods:
- A computational workflow was employed to dock a homology model of the DR6 ectodomain with a crystal structure of the growth factor-like domain of NAPP (GFD NAPP).
- The DR6 homology model was constructed using the neurotrophin p75 receptor as a template.
- Model selection was based on empirical binding affinity estimates, followed by verification against biophysical and theoretical data.
Main Results:
- A high-quality structural model of the DR6-GFD NAPP complex was generated, showing probable accuracy, particularly for GFD NAPP's residue contributions.
- Excellent agreement was observed between theoretically calculated and experimentally determined DR6-GFD NAPP binding free energy.
- The model provides a structural and energetic interpretation of the interaction, suggesting a mechanism for spontaneous apoptosis.
Conclusions:
- The developed DR6-NAPP binding model is considered accurate and valuable for future research.
- This model can aid in further computational studies, modeling efforts, and structure-based drug design for Alzheimer's disease.

